Abstract
It has been more than 20 yr since the first aldose reductase inhibitor was tested in diabetic and galactosemic rats and found to control polyol accumulation (1). Since then, a considerable number of aldose reductase inhibitors have been tested in experimental and human diabetes and have considerably increased our knowledge in this field (Table 1). A thorough review of work on experimental diabetes would be outside the scope of this volume; however, the interested reader can find more information in recently published extensive reviews. The following chapter will focus on the results from clinical trials in diabetic neuropathy (2,3).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Dvornik D, Simard-Duquesne N, Krami M, Sestanj K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 1973;182:1146–1148.
Sarges R, Oates PJ. Aldose reductase inhibitors: recent developments. Prog Drug Res 1993;40:99–161.
Tomlinson DR, Willars GB, Carrington AL. Aldose reductase inhibitors and diabetic complications. Pharmacol Ther 1992;54:151–194.
Dyck PJ, O’Brian PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 1989;12:649–652.
Culebras A, Alio J, Herrera JL, Lopez-Fraile IP. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Arch Neurol 1981;38:133,134.
Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 1981;30:459–464.
Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry 1981;44:991–1001.
Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte D. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983;308:119–125.
Jaspan J, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 1983;ii:758–762.
Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 1983;32:938–942.
Lewin IG, O’Brien AD, Morgan MH, Corrall RJM. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 1984; 26:445–448.
Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic neuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985;28:323–329.
O’Hare JP, Morgan MH, Alden P, Chissel S, O’Brien AD, Corrall RJM. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year’s treatment with sorbinil. Diabet Med 1988;5:537–542.
Guy RJC, Gilbey SG, Sheehy M, Asselman P, Watkins P. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 1988;31:214–220.
Consensus Statement. Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 1988;37:1000–1004.
Sima AAF, Brill V, Nathaniel T, McEwen TA, Brown MB Lattimer SA, Greene DA. Regeneration and repair of myelinated fibres in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548–555.
Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988;319:542–548.
Gill JS, Williams G, Ghatei MA, Hetreed AH, Mather HM, Bloom SR. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabetes Metab 1990;16:296–302.
Price DE, Alani SM, Wales JK. Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects. Diabetes Care 1991;14:411–413.
Ziegler D, Mayer P, Rathmann W, Gries FA. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 1991;14:63–73.
Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 1992;9:463–468.
Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431–437.
Macleod AF, Boulton AJM, Owens DR, Van Rooy P, Van Gerven JMA, MacRury S, Scarpello JHB, Segers O, Heller SR, Van der Veen EA. A multicentre trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy. Diabete et Metab 1992;18:14–20.
Santiago JV, Sonksen PH, Boulton AJM, Macleod A, Beg M, Bochenek W, Graepel GJ, Conen B. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function. J Diab Comp 1993;7:170–178.
Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B. Effect of hyperglycemia and the aldose inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diab Comp 1993;7:157–169.
Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo controlled trial. Ann Int Med 1993;118:7–11.
Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L, Ceriello A, Quatraro A, D’Onofrio F. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536–541.
Greene DA, Arezzo J, Brown M. Dose-related effects of the aldose reductase inhibitor zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fiber density in human diabetic neuropathy. Diabetes 1996;45(Suppl. 2):5A(abstract).
Greene DA, Arezzo JC, Klioze SS, Peterson MJ, Lakshminary MY. Results of phase II multicenter study of zopolrestat in patients with peripheral diabetic neuropathy. Diabetologia 1996;39(Suppl. l):A35(abstract).
Jamal GA. The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetic Med 1994;11:145–149.
Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double blind placebo controlled trial. Diabetic Med 1990;7:319–323.
Keen H, Payan J, Allawi J. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.
Boulton AJM, Ziegler D, Scarpello J, Jamal GA, Keen H, Aimer LO, Gamstedt A. A multicenter double-blind trial of gamolenic acid in diabetic peripheral sensorimotor neuropathy. Diabetologia 1997;40(Suppl. l):A32(abstract).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Veves, A. (1998). Aldose Reductase Inhibitors and Other Potential Therapeutic Agents for the Treatment of Diabetic Neuropathy. In: Veves, A. (eds) Clinical Management of Diabetic Neuropathy. Contemporary Endocrinology, vol 7. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-1816-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4612-1816-6_8
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4612-7296-0
Online ISBN: 978-1-4612-1816-6
eBook Packages: Springer Book Archive